Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer

ConclusionsAddition of carboplatin to neoadjuvant chemotherapy significantly improved DFS and OS in patients with TNBC but not in those with hormone receptor-positive, HER2-negative breast cancer.

Source: Breast Cancer Research and Treatment - March 4, 2020 Category: Cancer & Oncology Source Type: research